HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Herbalife Shakes Up Executive Suite Due To CEO's Earlier Statements On Expenses

Executive Summary

Herbalife announced following close of trading on US exchanges that former CEO and current Chairman Michael Johnson returns as interim chief following Richard Goudis' resignation.The firm, which has yet to schedule the release of its 2018 fourth-quarter results, said Goudis’ exit "pertains to comments which recently came to light" he made prior to becoming CEO in 2017.

You may also be interested in...



Wellness Market Executive Decisions: Herbalife Succession, CRN, Pharmavite, USANA Appointments

Herbalife CEO, president changes effective in March; CRN appoints Julia Gustafson VP of government relations; Pharmavite names Rhonda Hoffman chief marketing officer; and USANA promotes Walter Noot to COO.

Health, Beauty And Wellness News: Herbalife Q3, NPA On Part 111 Trends, AHPA's Zimmerman Awarded

AHPA's Zimmerman receives AHG's 'Best Contribution' award; NPA notes Part 111 violations common and emerging; saw palmetto BAPP update notes adulteration developments; China results lead Herbalife sales jump; and China deal delay moves GNC Q3 report date.

MJ, RB Shareholders Approve Deal: Health & Wellness News Roundup

Mead Johnson and Reckitt Benckiser shareholders approve acquisition; Pacific Herb pain product has AMA billing code; NeuEnergy available in Esso stores; eGamerz energy supplement launches online; more news in brief.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS148421

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel